DUX4 and neoplasm: For B-ALL, the findings by Chang et al. were substantiated by neo-epitope prediction in nine patients (seven with ETV6-RUNX1 and two with DUX4-IGH) based on tumor and germline whole-genome sequencing (WGS), whole-exome sequencing and tumor mRNA sequencing.